Grade 3 IDH1-mutant Glioma
1 clinical trials · Condition
◉ Watch Grade 3 IDH1-mutant Glioma
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease (NCT07703436) | Nuvation Bio Inc. | 2027-03-01 |
Track Grade 3 IDH1-mutant Glioma automatically
Every clearance here is in the API, with alerts when new ones post.